ArticleIntegrative zoology2026
Adaptive Evolution of FOXO Family Regulating Lifespan Extension and Cancer Resistance in Long-Lived Species.
Article in Integrative zoology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The extension of lifespan has evolved independently multiple times in mammals. Long-lived species exhibit markedly lower cancer mortality rates, indicating that they may have evolved enhanced cancer resistance to accommodate their prolonged lifespan. The FOXO protein family is considered to play key roles in modulating lifespan and cancer resistance in model organisms. However, the underlying molecular mechanisms of the FOXO protein family regulating lifespan extension and cancer resistance in long-lived species remain poorly understood. Here, evolutionary analysis of four FOXO genes across 137 mammalian species revealed all the four genes were under overall purifying selection. Nonetheless, we detected modestly elevated ω values in long-lived lineages relative to background groups, and 18 positively selected sites were identified in the four FOXO genes in long-lived mammals. To further test whether these FOXO genes have occurred functional changes, we selected FOXO3 and FOXO4 to perform functional validation. Cell experiments demonstrated that bowhead whale FOXO3 and FOXO4 significantly inhibited HeLa cell proliferation, migration, and invasion. Subcellular localization assays showed that mouse FOXO3 and FOXO4 were mostly distributed in the cytosolic cytoplasm, whereas bowhead whale FOXO3 and FOXO4 were predominantly localized in the nucleus, which may increase transcriptional activity and inhibit tumorigenesis in cetaceans. In particular, bowhead whale FOXO3 was found to upregulate the tumor suppressors PTEN and FASL while downregulating the oncogene BCL6, suggesting that this FOXO3-driven expression pattern may underlie cancer resistance in long-lived mammals. Overall, our findings provide novel insights into the molecular mechanisms underlying the cancer resistance in mammals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.